We are proud to share that heecap, one of our portfolio companies at Nara Health Capital, has had a remarkable presence at the Mobile World Capital Barcelona (MWC) 2025. This global event serves as a hub for the most cutting-edge technologies worldwide, and Heecap has proven to be at the forefront with its revolutionary respiratory health solution: "Active Breathing." Additionally, its CEO, Laura Lizama, represented Heecap exceptionally well at the EIC - European Innovation Council's "Women Tech EU" event, highlighting the importance of female talent in technology and innovation. Heecap is revolutionizing respiratory care with its innovative electrical stimulation device, designed to activate respiratory muscles in ICU patients on assisted breathing in a non-invasive and personalized manner. At Nara Health Capital, we remain committed to supporting Heecap in its mission to revolutionize respiratory health and to its CEO as a leading figure in female leadership in MedTech.
Nara Capital
Entidades de capital riesgo y capital privado
Barcelona, Catalonia 2631 seguidores
Sector-focused transformational investments
Sobre nosotros
NARA is an multi-strategy investment firm with the purpose of making a positive difference in the society and environment. The company is a regulated AIFM under the authorization and supervision of the Spanish Securities and Exchange Commission (CNMV). We currently manage 3 strategies: NARA VENTURES is a fund of top tier VC funds that invests globally. We co-manage the fund with PlugAndPlay, a pioneer investor in Silicon Valley with more than 35 unicorns. NARA HEALTH backs purpose driven entrepreneurs who are reimagining healthcare. Just like IT has changed the world BIO is on the precipice of changing every aspects of our lives. NARA HEALTH has been the winner of the 14th Fond-ICO call in the Tech Transfer category. NARA SUSTAINABILITY accelerates the transformation of the energy sector towards a Net-Zero world. The fund invests in the origination and development of new projects in photovoltaic solar, wind, hydrogen and storage.
- Sitio web
-
https://www.nara.capital
Enlace externo para Nara Capital
- Sector
- Entidades de capital riesgo y capital privado
- Tamaño de la empresa
- De 11 a 50 empleados
- Sede
- Barcelona, Catalonia
- Tipo
- De financiación privada
Ubicaciones
-
Principal
Cómo llegar
Avinguda Diagonal, 534
Barcelona, Catalonia 08006, ES
Empleados en Nara Capital
Actualizaciones
-
Last month Biocat, BioRegion of Catalonia & Expansión published the top funding rounds in 2024 in Cataluña. Great to see three of our portfolio companies highlighted among them. BIOINTAXIS – Advancing gene therapy to address the root cause of Friedreich’s Ataxia, a hereditary neurodegenerative disease with no curative treatment options. Gyala Therapeutics – Developing CAR-T therapies with novel targets for haematological cancers. heecap – Creating an innovative device that synchronizes muscular stimulation with patient breathing to strengthen respiratory muscles in ICU patients. Proud to support these teams as they drive disruptive advances for patients.
-
-
We're #hiring a new Junior Controller in Barcelona, Catalonia. Apply today or share this post with your network.
-
We're #hiring a new Investment Analyst in Barcelona, Catalonia. Apply today or share this post with your network.
-
We're #hiring a new Chief Financial Officer in Barcelona, Catalonia. Apply today or share this post with your network.
-
We're #hiring a new Chief Financial Officer in Barcelona, Catalonia. Apply today or share this post with your network.
-
Congratulations Asabys Partners, this success adds to your position as one of the key innovation investors in the HealthTech sector.
Today we are excited to announce that we have successfully closed the Sabadell Asabys Health Innovation Investments II (SAHII II) fund with total commitments of €180M, surpassing our initial target of €150M. Our second fund will invest in 12-15 companies across biopharma, medtech, and digital health, focusing on solutions for unmet medical needs and improving patient outcomes. Key details: ● Fund II already invested in 5 companies so far: deepull, Orikine Bio, Gradient Denervation Technologies, ALLOX and Augustine Therapeutics. ● SAHII II welcomes new US and international investors, as well as recurring investors from SAHII I such as Banco Sabadell, European Investment Fund (EIF), Alantra. ● To date, Asabys raised close to €300M in AUM, invested in 17 companies since its inception in 2018. Our team of 11 professionals, supported by venture partners and advisors, is committed to investing in life sciences companies developing novel solutions for unmet medical needs building on solid scientific evidence and a clear benefit for patients. https://lnkd.in/ds-xsx7X #SAHII #Biopharma #Medtech #LifeSciences
-
-
We're #hiring a new Private Equity Trainee in Barcelona, Catalonia. Apply today or share this post with your network.